Bryn Mawr Trust CO Erasca, Inc. Transaction History
Bryn Mawr Trust CO
- $5.88 Billion
- Q3 2025
A detailed history of Bryn Mawr Trust CO transactions in Erasca, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 431 shares of ERAS stock, worth $995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
431Holding current value
$995% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
153Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$52.5 Million1.52% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.3MShares$47 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$41.2 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$34.7 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$33.5 Million0.63% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $282M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...